Immunosuppressants and immunosuppressive treatments
| Calcineurin inhibitors | Cytotoxic agents | mTOR inhibitors | Steroids | Biologics | Monoclonal antibodies |
|---|---|---|---|---|---|
| Tacrolimus (Crohn; non-FDA) Cyclosporine (UC; non-FDA) | Mycophenolate Azathioprine (IBD; non-FDA) Leflunomide (Crohn; non-FDA) Chlorambucil Cyclophosphamide Mercaptopurine (IBD; non-FDA) Methotrexate (Crohn; non-FDA) Platinum compounds Fluorouracil Dactinomycin | Sirolimus Everolimus | Prednisone (IBD; FDA) Prednisolone (IBD; FDA) Budesonide (IBD; FDA) Dexamethasone (IBD; FDA) | Abatacept Adalimumab (IBD; FDA) Anakinra Apremilast Certolizumab (Crohn; FDA) Etanercept (Crohn; non-FDA) Golimumab (UC; FDA) Infliximab (IBD; FDA) Ixekizumab Natalizumab (Crohn; FDA; (UC; non-FDA) Rituximab Secukinumab Tocilizumab Ustekinumab (Crohn; FDA) Vedolizumab (IBD; FDA) | Basiliximab Daclizumab Muromonab |
FDA = US Food and Drug Administration; IBD = inflammatory bowel disease; mTOR = mammalian target of rapamycin; UC = ulcerative colitis
Reprinted from Moscicki AB, et al. Guidelines for cervical cancer screening in immunosuppressed women without HIV infection. J Low Genit Tract Dis 2019; 23(2):87–101. doi:10.1097/LGT.0000000000000468 with permission from Wolters Kluwer Health.